Reports Q revenue $42.97M, consensus $41.4M. “We are pleased to report strong fourth quarter and full year results, including a record year in OA Pain Management. These results reflect the evolution of our differentiated HA franchise and the launch of exciting new products in Regenerative, Sports Medicine and Arthrosurface Joint Solutions,” said Cheryl Blanchard, Anika’s president and CEO. “Over the course of the year, we achieved key milestones, learned a lot about the business, and are taking decisive action to further reduce spending and focus our strategy on driving the products that provide the greatest growth opportunities. Our plan to optimize performance is designed to capitalize on the significant growth potential across the business while accelerating our pivot to profitability, with adjusted EBITDA expected to grow over 75% at the midpoint in 2024.”
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on ANIK:
- Anika Reports Fourth Quarter and Year-End 2023 Financial Results
- Anika Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- Anika to Issue Fourth Quarter and Year-End 2023 Financial Results on Wednesday, March 13, 2024
- Anika Therapeutics Announces Board Chair Transition
- Is ANIK a Buy, Before Earnings?